Value of high-density lipoprotein cholesterol in evaluating the severity and prognosis of hepatitis B virus-associated acute-on-chronic liver failure

Ying XU; Xiaoping HUANG; Li CHEN; Wei SUN; Wenting LI; Yan WANG; Jianhe GAN

doi:10.3969/j.issn.1001-5256.2021.07.030

Volume 37 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(7): 1632-1635

PDF( 2128 KB)

Value of high-density lipoprotein cholesterol in evaluating the severity and prognosis of hepatitis B virus-associated acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.07.030

Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China

Research funding:

National Ministry of Science and Technology, the 13th Five-Year Major Project (2017ZX10203201002-002)

Received Date: 2020-11-28
Accepted Date: 2021-01-21
Published Date: 2021-07-20

Abstract

Abstract

Objective To investigate the association of high-density lipoprotein cholesterol (HDL-C) with the prognosis of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) and its predictive value. Methods The patients with liver disease who were admitted to Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, from January 2015 to January 2019 were enrolled, and according to the stage of disease progression, they were divided into HBV-ACLF group with 42 patients, liver cirrhosis group with 30 patients, and chronic hepatitis group with 25 patients. A total of 24 healthy individuals were enrolled as healthy control group. General clinical data were collected, including sex, age, prothrombin time (PT), albumin (Alb), total bilirubin (TBil), serum creatinine, blood urea nitrogen (BUN), total cholesterol (TC), triglyceride (TG), HDL-C, low-density lipoprotein cholesterol (LDL-C), and Model for End-Stage Liver Disease (MELD) score. The HBV-ACLF group was further divided into improvement group with 17 patients and non-improvement group with 25 patients, and the patients were followed up for 3 months. The Mann-Whitney U test was used for comparison of non-normally distributed continuous variables between two groups; the Kruskal-Wallis H test was used for comparison between multiple groups, and the Wilcoxon rank-sum test was used for comparison within each group. A binary logistic regression analysis was used to investigate independent risk factors for prognosis, and the receiver operating characteristic (ROC) curve was used to evaluate the accuracy of the variables in prediction. Results There were significant differences in PT, Alb, BUN, TBil, TC, TG, HDL-C, LDL-C, and MELD scores between the liver cirrhosis group, the HBV-ACLF group, the chronic hepatitis group, and the healthy control group (χ²=75.134, 44.638, 10.253, 80.357, 55.067, 19.858, 68.174, 52.492, and 64.359, all P < 0.05). Further comparison between two groups showed that the HBV-ACLF group had a significantly lower level of HDL-C than the liver cirrhosis group [0.12 (0.08-0.30) mmol/L vs 0.79 (0.60-1.01) mmol/L, Z=3.821, P < 0.001], the chronic hepatitis group [0.12 (0.08-0.30) mmol/L vs 1.06(0.88-1.44) mmol/L, Z=5.921, P < 0.001], and the healthy control group [0.12 (0.08-0.30) mmol/L vs 2.03 (1.36-2.98) mmol/L, Z=7.228, P < 0.001]. The improvement group had a significantly higher level of HDL-C than the non-improvement group [0.20 (0.11-0.49) mmol/L vs 0.10 (0.07-0.15) mmol/L, Z=-1.628, P=0.014]. The binary logistic regression analysis showed that HDL-C (odds ratio [OR]=0.003, 95% confidence interval [CI]: 0-0.548, P=0.029) and MELD score (OR=1.588, 95%CI: 1.032-2.443, P=0.035) were independent influencing factors for the prognosis of HBV-ACLF. HDL-C had an area under the ROC curve (AUC) of 0.807 in predicting the prognosis of HBV-ACLF, with a sensitivity of 0.706, a specificity 0.800, and a 95% CI of 0.677-0.937 at the optimal cut-off value of 0.175 mmol/L; MELD score had an AUC of 0.822, with a sensitivity of 0.760, a specificity of 0.765, and a 95% CI of 0.696-0.928 at the optimal cut-off value of 26.500. Conclusion HDL-C is an independent risk factor for the prognosis of patients with HBV-ACLF and has a good value in predicting the prognosis of HBV-ACLF.
- Hepatitis B Virus,
- Acute-on-chronic Liver Falure,
- Cholesterol, HDL,
- Prognosis

FullText(HTML)

References(19)

References

[1]	ANNEMA W, TIETGE UJ. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies[J]. Nutr Metab (Lond), 2012, 9(1): 25. DOI: 10.1186/1743-7075-9-25.
[2]	ETOGO-ASSE FE, VINCENT RP, HUGHES SA, et al. High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness[J]. Liver Int, 2012, 32(1): 128-136. DOI: 10.1111/j.1478-3231.2011.02657.x.
[3]	TSAI MH, PENG YS, CHEN YC, et al. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis[J]. J Hepatol, 2009, 50(5): 906-915. DOI: 10.1016/j.jhep.2008.12.024.
[4]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[5]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[6]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[7]	van LEEUWEN HJ, HEEZIUS EC, DALLINGA GM, et al. Lipoprotein metabolism in patients with severe sepsis[J]. Crit Care Med, 2003, 31(5): 1359-1366. DOI: 10.1097/01.CCM.0000059724.08290.51.
[8]	DELGADO-COELLO B, BRIONES-ORTA MA, MACÍAS-SILVA M, et al. Cholesterol: Recapitulation of its active role during liver regeneration[J]. Liver Int, 2011, 31(9): 1271-1284. DOI: 10.1111/j.1478-3231.2011.02542.x.
[9]	MANKA P, OLLIGES V, BECHMANN LP, et al. Low levels of blood lipids are associated with etiology and lethal outcome in acute liver failure[J]. PLoS One, 2014, 9(7): e102351. DOI: 10.1371/journal.pone.0102351.
[10]	CHRISTOU L, PAPPAS G, FALAGAS ME. Bacterial infection-related morbidity and mortality in cirrhosis[J]. Am J Gastroenterol, 2007, 102(7): 1510-1517. DOI: 10.1111/j.1572-0241.2007.01286.x.
[11]	HUANG XP, WANG Y, CHEN L, et al. Elevated serum prostaglandin E2 predicts the risk of infection in hepatitis B virus-related acute-on-chronic liver failure patients[J]. Asian Pac J Trop Med, 2017, 10(9): 916-920. DOI: 10.1016/j.apjtm.2017.08.008.
[12]	KIM HY, CHANG Y, PARK JY, et al. Characterization of acute-on-chronic liver failure and prediction of mortality in Asian patients with active alcoholism[J]. J Gastroenterol Hepatol, 2016, 31(2): 427-433. DOI: 10.1111/jgh.13084.
[13]	OKADA N, SANADA Y, URAHASHI T, et al. Endotoxin metabolism reflects hepatic functional reserve in end-stage liver disease[J]. Transplant Proc, 2018, 50(5): 1360-1364. DOI: 10.1016/j.transproceed.2018.01.052.
[14]	WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60(1): 197-209. DOI: 10.1016/j.jhep.2013.07.044.
[15]	SANADA Y, MIZUTA K, URAHASHI T, et al. Impact of hepatic clearance of endotoxin using endotoxin activity assay[J]. Hepatol Int, 2012, 6(4): 778-782. DOI: 10.1007/s12072-011-9289-4.
[16]	CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
[17]	TRIEB M, RAINER F, STADLBAUER V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure[J]. J Hepatol, 2020, 73(1): 113-120. DOI: 10.1016/j.jhep.2020.01.026.
[18]	LEVINE DM, PARKER TS, DONNELLY TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein[J]. Proc Natl Acad Sci U S A, 1993, 90(24): 12040-12044. DOI: 10.1073/pnas.90.24.12040.
[19]	FESSLER MB, PARKS JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling[J]. J Immunol, 2011, 187(4): 1529-1535. DOI: 10.4049/jimmunol.1100253.

Relative Articles

[1]	Lixian WU, Weiqiang ZHENG, Huanqin HAN. Effect of different antiviral drugs in reducing the risk of hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1165-1168. doi: 10.3969/j.issn.1001-5256.2022.05.040
[2]	Mingyang FENG, Hui WANG. Selection of antiviral drugs for patients with hepatitis B virus-associated hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2452-2456. doi: 10.3969/j.issn.1001-5256.2022.11.004
[3]	Jing LI, Yu CAO, Yongmei FENG, Yuanqiang GUO, Bei JIANG, Chunyan WANG. HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy with nucleos(t)ide analogues and its clinical significance[J]. Journal of Clinical Hepatology, 2021, 37(10): 2324-2326. doi: 10.3969/j.issn.1001-5256.2021.10.013
[4]	CHEN HongYu, XU XiaoYuan. Drug resistance of direct-acting antivirals in genotype 2/3 hepatitis C virus[J]. Journal of Clinical Hepatology, 2020, 36(11): 2553-2556. doi: 10.3969/j.issn.1001-5256.2020.11.035
[5]	You GuoQiong, Wang Li, Duan Meng, Zhu Peng. Research advances in direct-acting antiviral agents in the treatment of hepatitis C virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(1): 187-190. doi: 10.3969/j.issn.1001-5256.2019.01.041
[6]	Ning HuiBin, Liu JunPing, Jin HuiMing, Li Kuan, Xiao ErHui, Shang Jia. Direct-acting antiviral durgs for hepatitis C in children: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 164-165. doi: 10.3969/j.issn.1001-5256.2019.01.032
[7]	Zhang JieBing, Guo HongHua. Research advances in hepatitis B cirrhosis with renal injury and the application of antiviral drugs[J]. Journal of Clinical Hepatology, 2019, 35(1): 191-196. doi: 10.3969/j.issn.1001-5256.2019.01.042
[8]	Wang MengLan, Tang Hong. Drug-drug interaction of direct-acting antivirals in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2018, 34(2): 229-232. doi: 10.3969/j.issn.1001-5256.2018.02.002
[9]	Wang HuiJuan, Duan ZhongPing, Zhang HuanHu, Ren Feng. Research advances in the application of antiviral drugs during pregnancy for blocking mother-to-child transmission of hepatitis B virus[J]. Journal of Clinical Hepatology, 2018, 34(10): 2208-2212. doi: 10.3969/j.issn.1001-5256.2018.10.032
[10]	Zhang Xi, Li YongGuo. Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems[J]. Journal of Clinical Hepatology, 2018, 34(4): 853-857. doi: 10.3969/j.issn.1001-5256.2018.04.034
[11]	Zhao XiTai, Nie QingHe. Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1067-1074. doi: 10.3969/j.issn.1001-5256.2017.06.010
[12]	Wang Cheng, Liao JiaJie. Treatment of HBV/HCV co-infected patients in DAA era[J]. Journal of Clinical Hepatology, 2017, 33(6): 1011-1016. doi: 10.3969/j.issn.1001-5256.2017.06.001
[13]	Ceng Qun, Jie ShengHua. Research advances in antiviral drugs and their treatment regimens in chronic hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2200-2204. doi: 10.3969/j.issn.1001-5256.2017.11.033
[14]	Bian DanDan, Zheng SuJun. Influencing factors for the therapeutic effect of direct-acting antiviral agents in hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2205-2208. doi: 10.3969/j.issn.1001-5256.2017.11.034
[15]	Chen XinYue, Liu YaLi, Ren Shan. Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1063-1066. doi: 10.3969/j.issn.1001-5256.2017.06.009
[16]	Wen XiaoYu, Niu JunQi. Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(9): 1699-1705. doi: 10.3969/j.issn.1001-5256.2016.09.013
[17]	Zhang Yu, Cao Ying, Zhang RenWen, Zhang XiaXia, Lu HaiYing, Wu ChiHong, Huo Na, Yu Min, Liu Dan, Xu XiaoYuan. Natural resistance mutations to direct- acting antiviral agents in interferon / ribavirin treatment- experienced and treatment- nave patients with chronic hepatitis C in Beijing,China[J]. Journal of Clinical Hepatology, 2016, 32(4): 711-715. doi: 10.3969/j.issn.1001-5256.2016.04.020
[18]	Zhang Jing, Liu XueMin, Liu ZhengWen, Lu: Yi. Application of direct-acting antiviral agents in perioperative period of liver transplantation for patients with hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(12): 2084-2087. doi: 10.3969/j.issn.1001-5256.2015.12.023
[19]	Ren Shan, Chen XinYue. Current research on hepatitis C virus resistance to direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2015, 31(11): 1807-1812. doi: 10.3969/j.issn.1001-5256.2015.11.010
[20]	Deng Le, Wen ZhiLi. Review of recent research progress in correlating HBV genotypes with efficacy of antiviral treatments[J]. Journal of Clinical Hepatology, 2012, 28(6): 469-473.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 陈红，刘庆丰，张要锋，李慧，吕丹，李婷. Lam和TDF治疗乙肝患者病毒耐药基因研究. 实验与检验医学. 2021(03): 555-558+562 .
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (533) PDF downloads(55)

Value of high-density lipoprotein cholesterol in evaluating the severity and prognosis of hepatitis B virus-associated acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.07.030

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Value of high-density lipoprotein cholesterol in evaluating the severity and prognosis of hepatitis B virus-associated acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.07.030

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content